- Rankings
- WIPR Insights
Jurisdiction Reports
Refine Search
Jurisdiction reports
Engagement in the international intellectual property family has played an active role in the rapid and sound development of China’s own IP system, as statistics show. 1 June 2010
Jurisdiction reports
The Ministry of Domestic Trade, Cooperatives & Consumerism (MDTCC) has recently looked into reviewing all IP acts in Malaysia. 1 June 2010
Jurisdiction reports
In a much-anticipated development, Israel is to accede to the Madrid Protocol on September 1, 2010. This will make it easier and cheaper for foreign entities to register marks in Israel. 1 June 2010
Jurisdiction reports
A Hungarian pharmaceutical company filed a trademark application for a colour/figurative use of the word ‘MultiKid’ with a list of goods. 1 June 2010
Jurisdiction reports
A recent decision of Germany’s Federal Supreme Court in Fischdosendeckel (Fish Tin Cap) concerns the somewhat strange case of negative statements about a competitor’s products in the specification of a patent. 1 June 2010
Jurisdiction reports
Brazil’s President Lula has enacted Provisional Measure No. 482, providing statutory authority to government agencies to issue compulsory licences, expropriate IP rights and suspend the obligation to maintain an IP regime with minimum standards, as provided by the TRIPs agreement. 1 April 2010
Jurisdiction reports
Individuals and small companies who own US patents encounter hurdles when faced with suing infringers, including the significant legal costs associated with representation. 1 April 2010
Jurisdiction reports
Although Turkey has followed international developments and harmonised its Trademark Law with EU legislation, the registration of non-traditional marks such as product packaging and product shape has not fallen into place. 1 April 2010
Jurisdiction reports
The new Implementing Regulations of the Chinese Patent Law became effective on February 1, 2010, together with the new Guidelines for Examination. 1 April 2010
Jurisdiction reports
The battle between original pharmaceuticals and their generic counterparts has always been about balancing public interest with a rigorous national intellectual property regime. 1 April 2010
Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.